Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1972 1
1977 1
1979 4
1981 7
1982 14
1983 12
1984 17
1985 18
1986 30
1987 30
1988 39
1989 38
1990 45
1991 37
1992 46
1993 37
1994 28
1995 36
1996 43
1997 34
1998 27
1999 23
2000 24
2001 24
2002 15
2003 17
2004 12
2005 16
2006 17
2007 11
2008 14
2009 14
2010 8
2011 10
2012 8
2013 13
2014 9
2015 11
2016 7
2017 11
2018 8
2019 3
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

804 results
Results by year
Filters applied: . Clear all
Page 1
Peptic ulcer disease
Malfertheiner P, et al. Lancet 2009 - Review. PMID 19683340
[The use of bismuth tripotassium dicitrate (De-Nol), a promising line of pathogenetic therapy for irritated bowel syndrome with diarrhea].
Iakovenko EP, et al. Klin Med (Mosk) 2008 - Clinical Trial. PMID 19069460 Russian.
The aim of the study was to assess the expediency of prescription and efficiency of bismuth tri-potassium di-citrate in different therapeutic schemes for the management of irritable bowel syndrome (IBS) dominated by diarrhea. ...
The aim of the study was to assess the expediency of prescription and efficiency of bismuth tri-potassium di-citrate in different the …
[Combined treatment of gastric ulcers induced by nonsteroid antiinflammatory drugs. Results of 4-week population-based controlled trial of efficacy of proton pump inhibitor combination with tripotassium bismuth dicitrate].
Karateev AE, et al. Ter Arkh 2009 - Clinical Trial. PMID 19663196 Russian.
AIM: To study efficacy of a combination of proton pump inhibitor (PPI) and bismuth tripotassium dicitrate (BTD) in gastric ulcers (GU) induced by non-steroid anti-inflammatory drugs (NSAD) in rheumatic patients with factors affecting PPI efficacy. ...
AIM: To study efficacy of a combination of proton pump inhibitor (PPI) and bismuth tripotassium dicitrate (BTD) in gast …
Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori.
Yang J, et al. Am J Gastroenterol 2019 - Clinical Trial. PMID 30807294
Patients were randomly allocated into 2 groups: the 14-day modified dual therapy group and the bismuth-containing quadruple therapy group. ...Furthermore, the cost of medications in the modified dual therapy was lower compared with that in the bismuth-containing quadruple therapy. ...
Patients were randomly allocated into 2 groups: the 14-day modified dual therapy group and the bismuth-containing quadruple therapy g …
Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB).
Lacey LF, et al. Eur J Clin Pharmacol 1994 - Clinical Trial. PMID 7859806
GR122311X (ranitidine bismuth citrate, Glaxo Group Research Ltd.) is a salt of ranitidine with a complex of bismuth and citric acid which is being developed for the treatment of peptic ulceration. In this study, 4 groups of 12 healthy male subjects were dosed for 10 days with either GR122311X 500 mg bid (301 mg bismuth per day), GR122311X 1.0 g bid (602 mg bismuth per day), tripotassium dicitrato bismuthate (TDB, DeNoltab, Gist Brocades Ltd., Weybridge, England) 240 mg bid (431 mg bismuth per day) or placebo. ...
GR122311X (ranitidine bismuth citrate, Glaxo Group Research Ltd.) is a salt of ranitidine with a complex of bismuth and citric …
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM, et al. Lancet 2016 - Clinical Trial. PMID 27769562
We aimed to compare the efficacy and safety of 10-day concomitant therapy, 10-day bismuth quadruple therapy, and 14-day triple therapy in the first-line treatment of H pylori. ...Patients were randomly assigned (1:1:1) to either concomitant therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily) for 10 days; bismuth quadruple therapy (bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day) for 10 days; or triple therapy (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily) for 14 days. ...
We aimed to compare the efficacy and safety of 10-day concomitant therapy, 10-day bismuth quadruple therapy, and 14-day triple therap …
Bismuth antimicrobial drugs serve as broad-spectrum metallo-β-lactamase inhibitors.
Wang R, et al. Nat Commun 2018. PMID 29382822 Free PMC article.
Here we show that an anti-Helicobacter pylori drug, colloidal bismuth subcitrate (CBS), and related Bi(III) compounds irreversibly inhibit different types of MBLs via the mechanism, with one Bi(III) displacing two Zn(II) ions as revealed by X-ray crystallography, leading to the release of Zn(II) cofactors. ...
Here we show that an anti-Helicobacter pylori drug, colloidal bismuth subcitrate (CBS), and related Bi(III) compounds irreversibly in …
Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial.
Lim H, et al. Medicine (Baltimore) 2018. PMID 30431605 Free PMC article.
However, there has been no comparative study of modified quadruple therapy with bismuth-containing quadruple therapy. The aim of this study is to compare the efficacy and safety of modified quadruple therapy with those of bismuth-containing quadruple therapy as a first-line regimen and to present the phenotypic and genotypic antibiotic resistance profile of H pylori. ...Subjects will be randomly allocated either to modified quadruple therapy (proton-pump inhibitor bid, amoxicillin 1 g bid, metronidazole 500 mg tid, bismuth subcitrate 300 mg qid daily) or bismuth-containing quadruple therapy (proton-pump inhibitor bid, tetracycline 500 mg qid, metronidazole 500 mg tid, bismuth subcitrate 300 mg qid daily) for 14 days. ...
However, there has been no comparative study of modified quadruple therapy with bismuth-containing quadruple therapy. The aim of this …
Bioavailability and chronic toxicity of bismuth citrate to earthworm Eisenia andrei exposed to natural sandy soil.
Omouri Z, et al. Ecotoxicol Environ Saf 2018. PMID 28822260
Adult earthworms were exposed to natural sandy soil contaminated artificially by bismuth citrate. Average total concentrations of bismuth in soil recovered by HNO(3) digestion ranged from 75 to 289mg/kg. ...After 28 days of exposure bismuth concentrations in earthworms tissue increased with increasing bismuth concentrations in soil reaching a stationary state of 21.37mg/kg dry tissue for 243mg Bi/kg dry soil total content. ...
Adult earthworms were exposed to natural sandy soil contaminated artificially by bismuth citrate. Average total concentrations of …
804 results
Jump to page
Feedback